Skip Navigation

Your Environment. Your Health.

TGF-Beta in Asthmatic Epithelial Cell Susceptibility to RSV Infection

Open for Recruitment

Study Background

The Role of TGF-Beta in Asthmatic Epithelial Cell Susceptibility to RSV Infection

Open for Recruitment

Asthma patients seem to be more prone to viral infections, and NIEHS scientists believe that the cells that line these patients' airways, cause this result by overproducing TGF-beta1, a protein that promotes viral growth. This study seeks participants with and without asthma to contribute airway cell samples.

For more information on this study, please visit the Clinical Trials Study page.

This content is available to use on your website.
Please visit NIEHS Syndication to get started.

Eligibility

Non-asthmatic & mild asthmatic participants 18-60 years of age. Candidates will be screened for eligibility over the phone and scheduled for a screening visit to confirm eligibility for the study.

What will you do?

  • This study involves a screening visit and a study visit.
  • Participants will be screened with a medical history and physical examination, as well as blood samples and a pulmonary function test.
  • At the study visit, participants will receive mild anesthetic and have a bronchoscopy, in which researchers insert a bronchoscope through the participant's nose and into the lungs to examine the lungs and collect lung cells.
  • Participants will be contacted by a research team member 24 to 36 hours after the bronchoscopy to ask about any side effects from the procedure .

What will NIEHS do?

This is a cross-sectional, controlled study designed to investigate whether Transforming Growth Factor-beta (TGF-beta) mediates increased asthmatic epithelial susceptibility to respiratory syncytial virus (RSV) infection by examining responses to RSV infection in epithelial cells cultured from asthmatic and non-asthmatic participants. Non-smoking healthy adults and mild asthmatics, aged 18-60 years old, will be recruited to participate. Potential participants will be prescreened and scheduled for a final eligibility visit that will include medical history review, vital signs, physical examination, blood draw, and pulmonary function tests (PFTs). After eligibility is confirmed, the participant will be scheduled for bronchoscopy. During the bronchoscopy, bronchial epithelia and alveolar macrophages will be obtained from the participant for analysis. Alveolar macrophages will be evaluated ex-vivo for inflammatory activity at baseline and after stimulation.

The primary objective of the laboratory analysis is to determine if TGF-beta mediates increased asthmatic epithelial susceptibility to RSV infection. The study has three aims which are interrelated: 1) To determine if asthmatic bronchial epithelia express more TGF-beta than normal epithelia; 2) to determine if RSV replication is greater in asthmatic epithelia than normal epithelia; and 3) to determine if TGF-beta mediates asthmatic bronchial epithelial susceptibility to RSV infections.

Study Location

NIEHS Clinical Research Unit (CRU) – Research Triangle Park, North Carolina, USA 27709

Protocol Number: 11-E-0006

Enrollment and Contact Information

To volunteer or learn more, contact Grace Isshiki at (919) 541-4973.

Principal Investigator

Stavros Garantziotis, M.D.
Stavros Garantziotis, M.D.
Medical Director, NIEHS Clinical Research Unit and Principal Investigator
Tel 919-541-9859
Fax 919-541-9854
garantziotis@niehs.nih.gov
P.O. Box 12233
Mail Drop CU-01
Durham, N.C. 27709